| A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. | |
| | |
MedLine Citation:
|
PMID: 20975033 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
M-atrial natriuretic peptide (ANP; M-ANP) is a novel next generation 40 amino acid peptide based on ANP, which is highly resistant to enzymatic degradation and has greater and more sustained beneficial actions compared with ANP. The current study was designed to advance our understanding of the therapeutic potential of M-ANP in a canine model of acute angiotensin II-induced hypertension with elevated cardiac filling pressures and aldosterone activation. We compare M-ANP with vehicle and equimolar human B-type natriuretic peptide, which possesses the most potent in vivo actions of the native natriuretic peptides. M-ANP significantly lowered mean arterial pressure and systemic vascular resistance. Importantly, despite a reduction in blood pressure, renal function was enhanced with significant increases in renal blood flow, glomerular filtration rate, diuresis, and natriuresis after M-ANP infusion. Although angiotensin II induced an acute increase in pulmonary capillary wedge pressure, M-ANP significantly lowered pulmonary capillary wedge pressure, pulmonary artery pressure, and right atrial pressure. Further, M-ANP significantly suppressed angiotensin II-induced activation of aldosterone. These cardiovascular and renal enhancing actions of M-ANP were accompanied by significant increases in plasma and urinary cGMP, the second messenger molecule of the natriuretic peptide system. When compared with human B-type natriuretic peptide, M-ANP had comparable cardiovascular actions but resulted in a greater natriuretic effect. These results suggest that M-ANP, which is more potent than ANP in normal canines, has potent blood pressure lowering and renal enhancing properties and may, therefore, serve as an ANP based therapeutic for acute hypertension. |
| | |
Authors:
|
Paul M McKie; Alessandro Cataliotti; Guido Boerrigter; Horng H Chen; S Jeson Sangaralingham; Fernando L Martin; Tomoko Ichiki; John C Burnett |
Related Documents
:
|
2139413 - Atrial natriuretic factor and autonomic nervous system function in man. 1279293 - Electrophysiologic and hemodynamic effects of h 234/09 (almokalant), quinidine, and (+)... 19673683 - Decreased placental oxygenation capacity in pre-eclampsia: clinical application of a no... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-10-25 |
Journal Detail:
|
Title: Hypertension Volume: 56 ISSN: 1524-4563 ISO Abbreviation: Hypertension Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-18 Completed Date: 2010-12-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7906255 Medline TA: Hypertension Country: United States |
Other Details:
|
Languages: eng Pagination: 1152-9 Citation Subset: IM |
Affiliation:
|
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA. mckie.paul@mayo.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Aldosterone / analysis Angiotensin II / pharmacology Animals Antihypertensive Agents / pharmacology Atrial Natriuretic Factor / metabolism, therapeutic use* Blood Pressure / drug effects Cyclic GMP / blood, urine Diuresis / drug effects Dogs Glomerular Filtration Rate / drug effects Humans Hypertension / chemically induced, drug therapy* Male Natriuresis / drug effects Pulmonary Wedge Pressure / drug effects Renal Circulation / drug effects Vascular Resistance / drug effects |
| Grant Support | |
ID/Acronym/Agency:
|
P01 HL76611/HL/NHLBI NIH HHS; R01 HL 36634/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 11128-99-7/Angiotensin II; 52-39-1/Aldosterone; 7665-99-8/Cyclic GMP; 85637-73-6/Atrial Natriuretic Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Regulation of 3',5'-cAMP in preglomerular smooth muscle and endothelial cells from genetically hyper...
Next Document: Is the deficiency of the long isoform of cellular FLICE-inhibitory protein involved in myocardial re...